---

Eduardo Avelleira holds a degree in Business Economics from the National University of Lanús (UNLa; 2004). He is currently an Associate Professor of subjects such as Business Plan and Current Problems of the Argentine Economy in the same degree, where he is also a Research Professor in the SME area. He is also Professor of related subjects in other careers at the UNLa.

He is General Manager of UBATEC S.A. since 2016, where he is responsible for the management and administration of the company.

He is LEAR (Legal Entity Appointed Representative) for the UNALAB Urban Nature Lab project of the European Union.

He is also signatory and administrator responsible for the management and administration of the following projects funded by the European Union:

- CONSENS, Latin American Consensus for the Internationalization in Postgraduate Education (Erasmus+ funding line), managed with the University of Buenos Aires;

- CRUZIVAX, Vaccine for the prevention and treatment of Trypanosoma Cruzi infection.

She is an Entity Administrator in the SAM (System of Award Management) of the Grants.gov (Registry of Providers of the US State), which allows her to manage funds, grants, scholarships and allocations from the US Government.

Eduardo Avelleira is Co-Director of Biomed Pl's Pseudovac Vaccine Project for Pseudomona, which is carried out by researchers from the Department of Biology and Introduction to Cell Biology of the School of Medicine of the University of Buenos Aires.

He received the prize of the 150⁰ Anniversary Contest of the Buenos Aires Stock Exchange for his paper presented on Capital Markets in 2004.

---

Dr. Emilio Malchiodi is a Biochemist and Dr. in Immunology from the University of Buenos Aires.

His PhD thesis was on the differential diagnosis of Chagas disease.

He completed his postdoctoral studies at the University of Maryland (USA), working in Biophysics and in the determination of the three-dimensional structure of proteins of immunological interest through X-ray crystallography.

He is currently Full Professor of the Chair of Immunology at the School of Pharmacy and Biochemistry of the University of Buenos Aires.

Emilio Malchiodi is a Senior Researcher at CONICET and Director of IDEHU, Institute for Humoral Immunity Studies, Prof. Dr. R.A. Margni (UBA-CONICET). He is currently developing vaccines for:

1. Chagas disease, based on chimeric antigens combined with state-of-the-art adjuvants;

2. Yellow Fever, based on Virus Like Particles (VLP) expressed in baculoviruses; and

3. Leishmaniasis, based on reverse vaccinology.

He is Future President (2021-2024) of the Latin American and Caribbean Association of Immunology (ALACI).

He has received numerous national and international grants to conduct research in the field of vaccines against parasitic diseases and in the interaction of macromolecules of the immune system that have led to the publication of more than 115 articles in scientific journals.

---

El Dr. Julián Rodriguez Talou es Licenciado en Ciencias Biológicas y Doctor de la Universidad de Buenos Aires.

Dr. Julián Rodriguez Talou has a BS in Biological Sciences and a PhD from the University of Buenos Aires.

He has done postdoctoral studies in the area of plant metabolic engineering under the supervision of Dr. R. Verpoorte at the Department of Pharmacognosy of the Univ. of Leiden (Netherlands).

He currently holds the position of Associate Professor of the Chair of Biotechnology at the School of Pharmacy and Biochemistry of the University of Buenos Aires and is an Independent Researcher (CIC) of CONICET.

He participates in the Dengue Vaccine Project of the NANOBIOTEC Institute (UBA CONICET).

His specialty is Plant Biotechnology, preferably related to the production of biomolecules of pharmaceutical interest.

He also develops other lines of work in the expression and production of virus antigens (Dengue and Chikungunya) for the design of diagnostic reagents.

He has published more than 45 scientific papers and has received the CAESPO 2007 award and the first UBATEC 2015 award for Innovation and Applied Research.

He has directed UBACYT, PICT, PIP projects and, at the international level, he has obtained a grant from the International Foundation for Science (IFS, Sweden).

He has participated in the teaching of numerous postgraduate courses at national and regional level and in the training of human resources, directing Doctoral and Master's Thesis.

---

Dr. María Victoria Miranda is a Biochemist with orientation in Biotechnology and PhD from the University of Buenos Aires.

She is currently a Senior Researcher at CONICET and is Full Professor in charge of the Chair of Biotechnology at the School of Pharmacy and Biochemistry of the University of Buenos Aires.

She is Director of the NANOBIOTEC Institute (UBA-CONICET), where she directs the Dengue Vaccine Project.

Her specialty is the expression and purification of recombinant proteins in the baculovirus/insect cell system.

She has published more than 70 scientific papers and is Co-author of 3 patents of invention. She has received several awards, including Innovar 2013 and UBATEC 2015 in the area of applied research.

She leads scientific research projects and participates in several agreements with national companies for the development of biotechnological processes.

She has experience with PDTS and PICT START UP projects. She has trained numerous human resources in the area of Biotechnology.

She is currently directing a project of the COVID-19 Extraordinary Call for Proposals.

---

Following the SARS CoV-2 pandemic in 2020, Silvia Colavecchia is the Director of the Preclinical Trials of the MVA MoCoV-2 Vaccine Project for COVID-19 of the University of Buenos Aires and UBATEC SA at the Vaccine Research Center of the Department of Immunology of the School of Veterinary Sciences.

Dr. Silvia Colavecchia has a degree in Biological Sciences (1996) and a PhD in Veterinary Sciences from the University of Buenos Aires (2011).

Since 2011, she is Head of Practical Works with exclusive dedication of the Chair of Immunology of the School of Veterinary Sciences of the University of Buenos Aires.

She is a member of the Vaccine Research Group of the Immunology Department of the School of Veterinary Sciences, where, in addition to directing the COVID-19 project, she is Co-Director of the West Nile Fever vaccine project and participates in the development of a vaccine for Paratuberculosis.

He participates in the research group of the Chair of Biology and Introduction to Cellular Biology of the School of Medical Sciences CBC of the University of Buenos Aires, where the project for the development of a polyvalent vaccine for Pseudomona is being carried out.

He has published numerous scientific papers on veterinary immunology.

---

More than 35 years dedicated to basic and applied research, development, clinical and preclinical trials and positioning of vaccines and vaccine serums in public and private organizations, companies and private research groups: OIE, PAHO, Lederle Cyanamid (USA), Connaught Laboratories (Canada), MMD (Lapi, Brazil), Finlay (Cuba), CIGB (Cuba), Berne (Switzerland), Crucell (Netherlands), Mériuex Institute (France), Mériuex Foundation (France). Consultant for more than 100 pharmaceutical companies specialized in vaccines in Latin America, USA, Canada, Africa, Europe, Asia, and Oceania.

Dr. Gabriel Capitelli is a Veterinarian graduated from the University of Buenos Aires (1985), holds a degree in Human Clinical Psychology (UAJFK, 2009) and a Diploma in Social and Political Anthropology (FLACSO, 2008).

He is a Doctor of Medicine in Internal Medicine (Behavior of Reservoir Transmitters of Zoonosis) and an Expert in Human Vaccines.

He is Professor of Biology and Introduction to Cellular Biology at the School of Medical Sciences CBC of the University of Buenos Aires.

He is the Director of the project for the development of a polyvalent vaccine for Pseudomona.

Following the SARS CoV-2 pandemic in 2020, Gabriel Capitelli serves as Scientific Coordinator of the Management and Monitoring Coordination of the COVID-19 Vaccine Project at the University of Buenos Aires and also as General Coordinator of the Research, Development and Production Unit of the MVA-MoCoV-2 Vaccine of UBATEC SA.

He is a member of the Vaccine Research Group of the Immunology Department of the School of Veterinary Sciences of the University of Buenos Aires, where he is involved, among other things, in the research of vaccines for Rabies, West Nile Fever, Paratuberculosis and COVID-19.